Amura's main research focus is the exploitation of the AMcore™ technology for the selective inhibition of CAC1 proteases.
Amura also has exclusive commericial and intellectual property rights to a broad spectrum ß-lactamase inhibitors (AM-112). This is an ideal protective combination product for otherwise resistance susceptible b-lactam antibiotics.
For more information on the Amura programmes, please use the sub-menus within the navigation pane on the left.
A molecular model of an Amura AMcore™ bicyclic inhibitor (ex WO2008007127) in the active site of cathepsin K